Leidos Stock Declines Amid Analyst Downgrades and Healthcare Portfolio Concerns

Leidos Stock Declines Amid Analyst Downgrades and Healthcare Portfolio Concerns

Leidos Holdings, Inc. (NYSE: LDOS), a prominent player in the defense, intelligence, and information technology services sector, has recently experienced a notable decline in its stock value. As of July 10, 2026, Leidos’ stock price stood at $107.02, reflecting a decrease of 1.76% from the previous close. This downturn is primarily attributed to recent analyst downgrades and emerging challenges within the company’s healthcare portfolio.

Analyst Downgrades Impact Stock Performance

In mid-June 2026, BofA Securities downgraded Leidos from a “Buy” to a “Neutral” rating, significantly reducing the price target from $200 to $125. The downgrade was primarily due to increasing pressures within Leidos’ healthcare segment. Despite acknowledging the strength of Leidos’ defense portfolio, BofA expressed concerns over the company’s ability to sustain profit margins amid uncertainties in U.S. defense spending. This downgrade contributed to a 1.3% decline in Leidos’ stock during pre-market trading on June 17, 2026.

Subsequently, on June 22, 2026, Leidos’ stock reached a new 52-week low of $106.08 following another downgrade by Wall Street Zen, which shifted its rating from “Buy” to “Hold.” This series of downgrades has intensified investor apprehension, leading to a sustained decrease in stock value.

Healthcare Portfolio Challenges

The downgrades are largely attributed to challenges within Leidos’ healthcare portfolio. Analysts have highlighted pressures in this segment, raising concerns about the company’s ability to maintain profit margins. While specific details regarding these challenges have not been disclosed, the healthcare sector’s complexities and evolving regulatory landscape may be contributing factors.

Financial Performance and Strategic Initiatives

Despite the recent stock decline, Leidos reported strong financial results in the first quarter of fiscal year 2026. The company achieved revenues of $4.4 billion, surpassing expectations, and adjusted EBITDA of $614 million. Net income for the quarter was $335 million, or $2.56 per diluted share. Additionally, Leidos raised its full-year guidance, projecting non-GAAP diluted earnings per share between $12.10 and $12.50.

In January 2026, Leidos announced the acquisition of ENTRUST Solutions Group for approximately $2.4 billion. This strategic move aims to bolster Leidos’ energy infrastructure portfolio and expand its presence in the utility gas and electric generation infrastructure markets. The acquisition is expected to be immediately accretive to revenue growth and EBITDA margin.

Dividend Declaration

On May 1, 2026, Leidos declared a quarterly cash dividend of $0.43 per share, payable on June 30, 2026, to stockholders of record as of June 15, 2026. This dividend reflects the company’s commitment to returning value to shareholders despite current market challenges.

Conclusion

Leidos Holdings, Inc. is navigating a period of stock volatility influenced by analyst downgrades and concerns within its healthcare portfolio. While the company continues to demonstrate strong financial performance and strategic growth initiatives, investor sentiment remains cautious. The coming months will be critical for Leidos as it addresses these challenges and strives to restore investor confidence.